Imbruvica Sales for Follicular Lymphoma across the US, Japan, and Five Major EU Markets, 2017-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Imbruvica” report has been added to ResearchAndMarkets.com’s offering. Imbruvica (ibrutinib; AbbVie/Johnson & Johnson) is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies. Imbruvica has been shown to inhibit these actions and … [Read more…]

The Global Japanese Encephalitis Vaccines Market will Rise by almost 9% Between, 2019-2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Japanese Encephalitis Vaccines Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. Global Japanese Encephalitis Vaccines Market: About this market The inclusion of vaccination against Japanese encephalitis in national immunization plans will lead to the expansion of the global Japanese encephalitis vaccines market at a CAGR of almost 9% during the forecast … [Read more…]

ADAO Releases Report Detailing EPA’s 30 Year Failure to Implement an Asbestos Ban

Report Looks at Public Health, Environmental, and Economic Impact of Continued Asbestos Use and Exposure WASHINGTON, D.C.–(BUSINESS WIRE)–#Cancer–The Asbestos Disease Awareness Organization (ADAO), the largest nonprofit dedicated to preventing asbestos caused-diseases, today released a new report detailing the inaction on the part of the EPA for the past 30 years to effectively ban asbestos. The … [Read more…]

Arzerra (ofatumumab; Genmab/Novartis) Drug Overview 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Arzerra” report has been added to ResearchAndMarkets.com’s offering. Arzerra (ofatumumab; Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation 20 (CD20) on the B-cell membrane. Arzerra binds effectively to both the small and large extracellular loops on CD20 and releases very slowly over … [Read more…]

Rituxan Drug Overview 2019: 2017 Arrival of a Biosimilar Version of Rituxan in the EU Further Dampens Rituxan’s Commercial Attractiveness – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Rituxan” report has been added to ResearchAndMarkets.com’s offering. Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo) is a murine/human chimeric cluster of differentiation (CD)20-targeted monoclonal antibody that is indicated for the treatment of a number of B-cell non-Hodgkin’s lymphomas and for rheumatoid arthritis patients who inadequately respond to anti-tumor necrosis factor therapy. Rituximab is marketed in the … [Read more…]

Louise Hogan Joins Korn Ferry as Senior Client Partner

LOS ANGELES–(BUSINESS WIRE)–Korn Ferry (NYSE:KFY) today announced Louise Hogan has joined the firm as a senior client partner. She specializes in healthcare and life sciences and is based in Korn Ferry’s Melbourne and Sydney offices. Hogan brings to the firm over 25 years commercial experience in health and life sciences and has held roles in … [Read more…]

InVivo Therapeutics Announces Postponement of Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that it has postponed its 2019 annual meeting of stockholders. The annual meeting, which was originally scheduled for June 11, 2019, had been adjourned until July 11, 2019 at 8:00 am Eastern Time. Less than a majority of the shares of the Company’s outstanding common … [Read more…]

Global Pneumonia Vaccines Market (2019-2025): Analysis on Prevnar 13, Synflorix, and Pneumovax 23 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Pneumonia Vaccines Market (2019-2025)” report has been added to ResearchAndMarkets.com’s offering. The Global Pneumonia Vaccines Market size is expected to reach $9.6 billion by 2025, rising at a market growth of 5.1% CAGR during the forecast period. The key factors that drive the growth of the global pneumonia vaccine market include an … [Read more…]

Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. as VP, Clinical Development

ROCKVILLE, Md.–(BUSINESS WIRE)–#allergies–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as VP, Clinical Development. Dr. Eisen is a translational medicine and clinical development specialist with over 20 years of experience in the biotech and pharma sectors. Prior to joining ITI, Dr. Eisen held executive-level … [Read more…]